Dare Bioscience
DARE
30 hedge funds and large institutions have $3.73M invested in Dare Bioscience in 2016 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 8 increasing their positions, 5 reducing their positions, and 6 closing their positions.
60% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 5
0% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 6
3% less funds holding
Funds holding: 31 → 30 (-1)
8.94% less ownership
Funds ownership: 28.17% → 19.23% (-8.9%)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
90% less capital inflows, than outflows
Capital inflows: $125K | Capital outflows: $1.21M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ARTA
A.R.T. Advisors
New York
|
+$47.1K |
| 2 |
Goldman Sachs
New York
|
+$26.9K |
| 3 |
Morgan Stanley
New York
|
+$16.7K |
| 4 |
Oxford Asset Management
Oxford,
United Kingdom
|
+$8K |
| 5 |
Tower Research Capital (TRC)
New York
|
+$3.72K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Granahan Investment Management
Waltham,
Massachusetts
|
-$755K |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$247K |
| 3 |
BlackRock Advisors
Wilmington,
Delaware
|
-$104K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$43.5K |
| 5 |
Virtu KCG Holdings
New York
|
-$18.3K |
DARE Hedge Fund Activity: Q4 2016 in Review
30 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Dare Bioscience (DARE) for Q4 2016, worth a combined $3.73M — down 54% from $8.07M a quarter earlier.
Fund positioning in DARE was balanced in Q4 2016: 6 funds opened new positions, 6 closed out, 8 added to existing stakes and 5 trimmed.
The largest buyer was A.R.T. Advisors, opening a new position worth an estimated $47.1K. The largest seller was Granahan Investment Management, exiting entirely with an estimated $755K sold.
- 30 institutional investors held Dare Bioscience (DARE) as of Q4 2016, down from 31 in Q3 2016.
- Funds reported $3.73M of Dare Bioscience stock for Q4 2016, down 54% quarter-over-quarter.
- 6 funds opened new Dare Bioscience positions in Q4 2016 and 6 closed out, a net change of 0 holders.
- The largest Dare Bioscience buyer in Q4 2016 was A.R.T. Advisors, an estimated $47.1K added.
- The largest Dare Bioscience seller in Q4 2016 was Granahan Investment Management, an estimated $755K sold.
Based on aggregated 13F filings for Q4 2016.